AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06439927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polycaprolactone nasal mesh
Description: a 3-dimensional fabricated Polycaprolactone nasal mesh
Study NCT05685160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI with contrast
Description: MRI of the forefoot with contrast (Gadovist)
Study NCT05685160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI with contrast
Description: MRI of the forefoot with contrast (Gadovist)
Study NCT05685160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound imaging of the forefoot
Study NCT05685160 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound imaging of the forefoot
Study NCT06585423 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sterile commercially available bandage contact lens
Description: Medical grade acrylic tip covered by a sterile commercially available bandage contact lens
Study NCT06585423 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Medical grade silicone of a thickness <100 µm
Description: Medical grade acrylic tip coated with medical grade silicone of a thickness \<100 µm
Study NCT06585423 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Medical grade silicone of a thickness >100 µm
Description: Medical grade acrylic tip coated with medical grade silicone of a thickness >100 µm
Study NCT05394116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Garetosmab
Description: Garetosmab is supplied as a liquid drug product and will be administered IV.
Study NCT05394116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV.
Study NCT06356350 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional neuromuscular exercises
Description: Conventional neuromuscular exercises represent a contemporary physiotherapeutic approach. These exercises aim to improve neuromuscular control, strength, and endurance in various muscles surrounding the included joint, contributing to the correction and maintenance of proper posture.
Study NCT06356350 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core based exercises
Description: Core based exercises increase overall mobility, relieve pain, improve posture, and support spinal alignment. Especially important for children who are still growing is to slow or stop the progression of deformities because of the asymmetrical loading pattern.
Study NCT05284747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab will be provided as a single-dose, prefilled autoinjector pen (AI/pen) for fixed dose subcutaneous (SC) injection.
Study NCT05284747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine Lipid Management
Description: Routine lipid management therapies will be administered at the discretion of the investigator per SoC.
Study NCT05284747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine Lipid Management
Description: Routine lipid management therapies will be administered at the discretion of the investigator per SoC.
Study NCT05936138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.
Study NCT05378425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTX-1088
Description: IgG4 mAb targeting the poliovirus receptor (PVR, CD155).
Study NCT05378425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IgG4 mAb with high specificity of binding to the PD-1 receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2).
Study NCT05832827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: Pembrolizumab will be administered at a dose of 200 mg by intravenous infusion every 21 days (3 weeks) for up to 35 cycles.
Study NCT05832827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be administered at a dose of 8 mg orally QD every 21 days (3 weeks) for up to 4 cycles in the induction phase, followed by 20 mg QD for up to 31 cycles in the maintenance phase. Then, further maintenance therapy with lenvatinib will be allowed until progression or unacceptable adverse events.
Study NCT04745858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bowen's Technique
Description: In Bowen's Technique, sequence of short gentle moves are applied over Hamstrings. Skin slack is taken to the lateral side of muscle. The muscle is hooked by the thumbs from its lateral edge. Skin is carried along and thumb is flattened in a medial direction, the muscle plucks under the thumbs. Three alternate sessions per week are given for 4 weeks. The treatment time for each session is 20 minutes.
Study NCT04745858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Energy Technique
Description: Isometric contraction of hamstrings is performed by the patient being employing 20% of the strength. This contraction is resisted by the practitioner for 7-10 s. A three second relaxation period is given. This technique is repeated for three times. Three alternate sessions per week is given for 4 weeks.
Study NCT05728983 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sleep levels
Description: Sleep levels are what the experimenter prescribes to participants in the study.
Study NCT05728983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep levels
Description: Sleep levels are what the experimenter prescribes to participants in the study.
Study NCT04864977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basal Insulin
Description: Participants administered basal insulin
Study NCT04525222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Receive motivational messages and smoking cessation information via text notifications
Study NCT04525222 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion and Education
Description: Receive motivational messages and smoking cessation information via text notifications
Study NCT04525222 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention (Actify app)
Description: Use Actify app
Study NCT05832827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered at a dose of AUC 5 intravenously every 21 days (3 weeks) for up to 4 cycles in the induction phase.
Study NCT05832827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 175 mg/m\^2 intravenously every 21 days (3 weeks) for up to 4 cycles in the induction phase.
Study NCT04525222 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Intervention (Current Standard Care app)
Description: Use (USCPG) Current Standard Care app
Study NCT04525222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT04525222 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05493618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV q3 weeks until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
Study NCT05493618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab 2.5 mg/kg IV q3 weeks until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
Study NCT05493618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg IV q3 weeks (20 mg if patient >75) until unacceptable toxicity or disease progression for up to 2 years (35 cycles).
Study NCT04864080 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer game/task
Description: N-back, COGED, PacMan game, Bandit task, Websurf task.
Study NCT06523387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment Online (PRT-O) Course
Description: Pivotal Response Treatment - Parent Training
Study NCT05528588 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Furoscix
Description: Study Drug: Furoscix®, (Furosemide Injection), 80 mg/10 mL is a proprietary furosemide formulation that is buffered to a neutral pH to enable subcutaneous administration and contained in a prefilled Crystal Zenith® (CZ) cartridge.~Study Device: The Infusor is a compact, ethylene oxide (EtO) sterilized, single-use, electro-mechanical (battery powered, micro-processor controlled), on-body subcutaneous delivery system based on the SmartDose® Gen II 10 mL (West Pharmaceutical Services).~The Furoscix Infusor is an investigational drug-device combination product. The Infusor is applied to the abdomen via a medical grade adhesive and delivers a subcutaneous infusion of Furoscix through a pre-programmed, biphasic delivery profile with 30 mg (3.75 mL) administered over the first hour, followed by 12.5 mg (1.56 mL) per hour for the subsequent 4 hours (Total dose is 80 mg (10 mL) over 5 hours).
Study NCT05528588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuretic Therapy
Description: Patients will receive home dose oral furosemide or oral furosemide per standard of care.
Study NCT06575595 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tulisokibart
Description: single dose via SC autoinjector (Treatment A) or concentration A or concentration B SC injection via syringe and vial (Treatments B and C)
Study NCT05997615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMX-500 (SAR446329)
Description: Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV) infusion
Study NCT05591300 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microparticles research
Description: The absolute count of the total circulating microparticles will be carried out on the patients' plasma using the NanoSight NS300 instrument (Alphatest). Furthermore, the circulating microparticles will be stained with a combination of three monoclonal antibodies (Becton and Dickinson, NJ,USA) to detect microparticles released by the most abundant cell populations in the blood: leukocyte-derived microparticles (CD45+), endothelial-derived microparticles (CD31+), and PLT-derived microparticles (CD31+ CD41a+).
Study NCT06479473 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy to all residual lesions
Description: Patients assigned to chemoimmunotherapy with radiotherapy group would first receive PET-CT and cranial contrasted MRI to ascertain residual lesions. All residual lesions would be irradiated in a hypofractionated manner.
Study NCT06116591 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mPnC candidate
Description: monovalent pneumococcal conjugate candidate
Study NCT06116591 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mPnC control
Description: monovalent pneumococcal conjugate control
Study NCT05014698 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: WGS
Description: Whole Genome sequencing
Study NCT06283095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: expansion palatoplasty
Description: surgical procedure
Study NCT05952167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive cervical traction protocol
Description: 2x/day over 5 weekdays A minimum of 8 pull-ups over 5 consecutive days is expected.
Study NCT05952167 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intensive cervical traction protocol - placebo
Description: 2x/day over 5 weekdays A minimum of 8 pull-ups over 5 consecutive days is expected.
Study NCT05360186 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MateRegen® gel (BioRegen)
Description: Modification of Hyaluronic acid structure to 3-dimensional self-cross-linked network structure enables all-dimensional coverage of tissue surface to enhance better healing process. Self-cross-linked HA hydrogels can maintain the biocompatibility and biodegradability that characterize the unmodified material. Moreover, high dynamic viscosity enables continuous indwelling in the uterine cavity. The gel could provide precise regulation, and degradation and absorption time prolonged to 7-14 days post operatively, which completely cover key postoperative healing period (5-7 days), at the highest time of intrauterine adhesion formation.
Study NCT05351086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUR3100
Description: PUR3100 is an inhalation powder containing DHE, an anti-migraine treatment with broad spectrum agonist activity against 5-hydroxytryptamine (5-HT), dopamine, and adrenergic receptors. PUR3100 is provided as 500 µg dose strength capsules. Each capsule contains the drug substance, DHE mesylate, with mannitol, leucine, and sodium chloride as excipients.
Study NCT05351086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (D.H.E 45)
Description: D.H.E. 45 is ergotamine hydrogenated in the 9, 10 position as the mesylate salt. It is supplied as a clear, colorless solution supplied in sterile ampules for IV, intramuscular, or subcutaneous administration containing (per mL) DHE mesylate, USP 1 mg, ethanol, 94% w/w. 6.2% by volume, glycerin 15% by weight, and water for injection.
Study NCT05351086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching Placebo for PUR3100
Description: Each capsule of matching placebo is filled with iSPERSE powder comprised of mannitol, leucine, and sodium chloride. The PUR3100 inhalation powder is administered using the supplied RS01 inhalation device (RS01 UHR2, Plastiape S.p.A.).
Study NCT05351086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching Placebo for D.H.E 45
Description: The matching placebo for D.H.E. 45 is 0.9% sterile saline for injection.
Study NCT06479473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemoimmunotherapy
Description: atients assigned to chemoimmunotherapy group would receive 4 to 6 cycles of chemoimmunotherapy followed by consolidative immunotherapy
Study NCT06479473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy
Description: atients assigned to chemoimmunotherapy group would receive 4 to 6 cycles of chemoimmunotherapy followed by consolidative immunotherapy
Study NCT04864080 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer game/task
Description: N-back, COGED, PacMan game, Bandit task, Websurf task.
Study NCT04864080 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health surveys online
Description: Health surveys to study themes like pain, sleep, depression and anxiety, and PTSD.
Study NCT04864080 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health surveys online
Description: Health surveys to study themes like pain, sleep, depression and anxiety, and PTSD.
Study NCT05990998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATATE and 68Ga-FAPI
Description: Each patient receive a single intravenous injection of 68Ga-FAPI or 68Ga-DOTATATE (2-4mCi) , and undergo PET/CT scan at 40-60 min post injection.
Study NCT05965297 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DeltaFil
Description: Cavities are prepared using rotary instruments/diamond burs. Afterwards, the cavity is conditioned (using DeltaFil conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer (DeltaFil). During the curing phase and after finishing Riva Coat will be applied to all restoration surfaces for moisture protection.
Study NCT05965297 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Riva Self Cure HV
Description: Cavities are prepared using rotary instruments/diamond burs. Afterwards, the cavity is conditioned (using Riva conditioner) and cleaned, with subsequent insertion of a conventional restorative glass-ionomer (Riva Self Cure HV). During the curing phase and after finishing Riva Coat will be applied to all restoration surfaces for moisture protection.
Study NCT06227026 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19 CAR-T cells
Description: Anti-CD19 CAR-T cells are autologous T cells, engineered to express an extracellular single chain variable fragment (scFv) derived from a murine anti-human CD19 hybridoma clone FMC63 linked in frame to hinge region derived from human CD8, transmembrane domain derived from Tumor Necrosis Factor Receptor Super Family 19 (TNFRSF19) the transactivation costimulatory domain 4-1BB, and CD3 zeta signaling domain (Miltenyi Biotec Inc). Anti-CD19 CAR-T cells will be cryopreserved in infusible cryomedia for a later infusion. Anti-CD19 CAR-T cells will be administered in 1 to 3 bags. Bag aliquoting, cell content and cryomedia composition will be done according to specifications in the CMC.
Study NCT05904548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF Ablation
Description: RF ablation for type I atrial flutter under iCMR guidance
Study NCT05197075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV/COBI FDC
Description: DRV/COBI FDC tablet dispersed in water will be administered orally.
Study NCT05281393 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEPresent
Description: PrEP2Prevent is being done in several phases (parts) to develop and pilot test a PrEP activation, navigation and support intervention for young men who have sex with men (YMSM), trans youth and non-binary youth in Los Angeles. It targets an intervention for these young people where they need it most - on PrEP uptake. PrEP stands for pre-exposure prophylaxis.
Study NCT04587531 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cranial Electrotherapy Stimulation
Description: Alpha-Stim® AID microcurrent and cranial electrotherapy stimulator will be used. Daily one hour cranial electrotherapy stimulation (CES) treatment using ear clip electrodes with current set at fixed level of 100 uA (a subsensory current level), 0.5 Hertz will be used for active CES treatment group for 6 weeks. For the sham group the Alpha-Stim® AID ear clips will not emit electricity.
Study NCT04587531 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Cranial Electrotherapy Stimulation
Description: Alpha-Stim® AID microcurrent and cranial electrotherapy stimulator will be used. Daily one hour cranial electrotherapy stimulation (CES) treatment using ear clip electrodes with current set at fixed level of 100 uA (a subsensory current level), 0.5 Hertz will be used for active CES treatment group for 6 weeks. For the sham group the Alpha-Stim® AID ear clips will not emit electricity.
Study NCT05072990 — intervention group
Intervention type: DRUG
Intervention: Chinese herb medicine
Description: Patients took 200 ml Chinese herb decoction twice a day before breakfast and dinner.
Study NCT03642795 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Patients are asked to complete several questionnaires
Study NCT06032403 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: flexible patient centred consultations
Description: In the intervention group, the set-up will be flexible patient-centred consultations. The first consultation for the participant will be with the doctor and depending on the participant's need, the following consultations can be scheduled as either a doctor- or a nurse consultation. After each consultation, it will be decided in collaboration between the healthcare professionals and the participant whether a nurse or a doctor consultation will be relevant next. The consultations (whether it is with the doctor or nurse) will be centered around the participant's choice of topics by use of an atopic dermatitis dialogue tool developed in the department. Additionally, the nurse consultation will focus on therapeutic patient education (TPE) in atopic dermatitis. The interval between consultations will depend on the participant's need
Study NCT05921162 — intervention group
Intervention type: BIOLOGICAL
Intervention: Gene Therapy product:vMCO-I
Description: Safety evaluation to monitor long term effects of previously injected vMCO-I in RP patients
Study NCT05226884 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Visual Acuity
Description: Measurement of distance and intermediate visual acuity at variety targeted correction.
Study NCT05226884 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Defocus Curve
Description: Measurement of a defocus curve
Study NCT05026632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPI-002 Intravitreal Implant
Description: Implant inserted during vitrectomy.
Study NCT04709939 — intervention group
Intervention type: OTHER
Intervention: OPAT
Description: Observation of patients who are discharged from the hospital on OPAT.
Study NCT04709939 — intervention group
Intervention type: OTHER
Intervention: Focus Group
Description: Focus group with infectious disease physicians who prescribe OPAT to patients but were not involved in the study.
Study NCT04323605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient assistance program for transplant patients (AMA-ALLO) based on a navigation nurse
Description: Integration of a post-transplant navigation nurse starting at the first post-transplant consultation (starting from D100 +/- 10 days post-transplant). Different times for post-transplant telephone monitoring (every week for the first 2 months, then every 15 days for the next 3 months then once a month for 7 months)